Chronix Biomedical announced today that it has filed a patent application for a diagnostic test that will help safeguard the blood supply, healthcare workers and patients. The patent application is for the detection of abnormal genetic material associated with Creutzfeldt-Jakob Disease (CJD), the human equivalent of “mad cow disease” or bovine spongiform encephalopathy (BSE). Blood donors in the U.S. are currently screened only with a written questionnaire; there is no blood test for CJD, which is 100% fatal. The Chronix test was developed to meet the public health need to halt the spread of CJD through the blood supply.
